| Obesity
Contrave vs Foundayo
Side-by-side clinical, coverage, and cost comparison for obesity.Deep comparison between: Contrave vs Foundayo with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsFoundayo has a higher rate of injection site reactions vs Contrave based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Foundayo but not Contrave, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Contrave
Foundayo
At A Glance
Oral
Twice daily
Opioid antagonist / NDRI combination
Oral
Daily
GLP-1 receptor agonist
Indications
- Obesity
- Obesity
Dosing
Obesity Dose escalation over 4 weeks to maintenance of 32 mg naltrexone/360 mg bupropion (two 8 mg/90 mg tablets twice daily) taken orally in morning and evening; not taken with high-fat meal; evaluate response after 12 weeks and discontinue if <5% weight loss.
Obesity Start at 0.8 mg orally once daily; escalate to 2.5 mg, then 5.5 mg, then optionally to 9 mg, 14.5 mg, or 17.2 mg (maximum) once daily, increasing at intervals of at least 30 days based on tolerability; take with or without food; swallow tablets whole.
Contraindications
- Uncontrolled hypertension
- Seizure disorder or history of seizures
- Concomitant use of other bupropion-containing products
- Bulimia or anorexia nervosa
- Chronic opioid or opiate agonist (e.g., methadone) or partial agonist (e.g., buprenorphine) use, or acute opiate withdrawal
- Abrupt discontinuation of alcohol, benzodiazepines, barbiturates, or antiepileptic drugs
- Concomitant use of MAOIs, including reversible MAOIs such as linezolid or intravenous methylene blue
- Known allergy to bupropion, naltrexone, or any other component of CONTRAVE
- Personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN 2)
- Known serious hypersensitivity to orforglipron or any excipient in FOUNDAYO
Adverse Reactions
Most common (>=2%) Nausea, constipation, headache, vomiting, dizziness, insomnia, dry mouth, diarrhea, anxiety, hot flush, fatigue, tremor, upper abdominal pain, viral gastroenteritis, influenza, tinnitus, urinary tract infection, hypertension, abdominal pain, hyperhidrosis, irritability, blood pressure increased, dysgeusia, rash, muscle strain, palpitations
Serious Suicidal behavior and ideation, neuropsychiatric adverse events, seizures, increase in blood pressure and heart rate, allergic reactions, angle-closure glaucoma
Postmarketing Loss of consciousness, malaise, Brugada pattern/syndrome, drug reaction with eosinophilia and systemic symptoms (DRESS), acute generalized exanthematous pustulosis (AGEP), aseptic meningitis
Most common (>=5%) Nausea, constipation, diarrhea, vomiting, dyspepsia, abdominal pain, headache, abdominal distension, fatigue, eructation, gastroesophageal reflux disease, flatulence, hair loss
Serious Thyroid C-cell tumors, acute pancreatitis, severe gastrointestinal reactions, acute kidney injury due to volume depletion, hypoglycemia, hypersensitivity reactions including anaphylaxis and angioedema, diabetic retinopathy complications, acute gallbladder disease, pulmonary aspiration during general anesthesia or deep sedation
Postmarketing Hemorrhagic and necrotizing pancreatitis sometimes resulting in death, ileus, intestinal obstruction, severe constipation including fecal impaction, anaphylaxis, angioedema, pulmonary aspiration, acute renal failure or worsening of chronic renal failure sometimes requiring hemodialysis
Pharmacology
CONTRAVE combines naltrexone, an opioid antagonist, and bupropion, a relatively weak inhibitor of the neuronal reuptake of dopamine and norepinephrine; together they act on the hypothalamus (appetite regulatory center) and the mesolimbic dopamine circuit (reward system) to reduce food intake and body weight, though the exact neurochemical effects are not fully understood.
Orforglipron is a small-molecule GLP-1 receptor agonist that binds to and activates the human GLP-1 receptor, reducing appetite and caloric intake by activating GLP-1 receptors in brain regions that regulate appetite and food intake, and also delays gastric emptying.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Contrave
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (0/12) · Qty limit (9/12)
Foundayo
- Covered on 5 commercial plans
- PA (8/12) · Step Therapy (0/12) · Qty limit (0/12)
UnitedHealthcare
Contrave
- Covered on 4 commercial plans
- PA (4/8) · Step Therapy (0/8) · Qty limit (0/8)
Foundayo
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Contrave
- Covered on 0 commercial plans
- PA (0/3) · Step Therapy (0/3) · Qty limit (0/3)
Foundayo
- Covered on 0 commercial plans
- PA (0/3) · Step Therapy (0/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Contrave.
$149/momo
Foundayo Self-Pay Savings Card ProgramCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
ContraveView full Contrave profile
FoundayoView full Foundayo profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.